Brazil forward Richarlison sustains suspected calf injury

Tottenham striker Richarlison sustained a suspected calf injury in his team's 4-0 loss to Liverpool on Thursday, coach Ange Postecoglou said.

The Brazil international was substituted just before halftime in the English League Cup semifinal second leg at Anfield.

“It looks like his calf. He didn't look too good after the game, so it's probably one to add to the list (of injured players),” Postecoglou said.

Richarlison has endured an injury-disrupted spell at Tottenham since joining from Everton in 2022.

He injured his calf early on in his first season and in 2023 underwent surgery on his groin. He was out earlier this season with a hamstring problem.

Liverpool won 4-1 on aggregate and will play Newcastle in the League Cup final on March 16.

James Robson is at https://twitter.com/jamesalanrobson

AP soccer: https://apnews.com/hub/soccer

Tottenham's Richarlison runs with the ball during the English League Cup semifinal second leg soccer match between Liverpool and Tottenham Hotspur at Anfield Stadium in Liverpool, England, Thursday, Feb. 6, 2025. (AP Photo/Jon Super)

Tottenham's Richarlison leaves the field injured during the English League Cup semifinal second leg soccer match between Liverpool and Tottenham Hotspur at Anfield Stadium in Liverpool, England, Thursday, Feb. 6, 2025. (AP Photo/Jon Super)

Tottenham's Richarlison gets treatment before leaving the field injured during the English League Cup semifinal second leg soccer match between Liverpool and Tottenham Hotspur at Anfield Stadium in Liverpool, England, Thursday, Feb. 6, 2025. (AP Photo/Jon Super)

Tottenham's Richarlison gets treatment before leaving the field injured during the English League Cup semifinal second leg soccer match between Liverpool and Tottenham Hotspur at Anfield Stadium in Liverpool, England, Thursday, Feb. 6, 2025. (AP Photo/Jon Super)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Jan 12, 2026--

ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To support its growth in the region, ChemWerth has hired Chandrakanth Reddy as general sales manager of its India office.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260111302280/en/

“The addition of a general sales manager in India signals our desire to grow our presence and customer base in the world’s most important generic pharmaceutical market,” said Pete Werth III, president, ChemWerth. “Chandrakanth will add tremendous value for our customers and contract manufacturing organizations (CMOs) in India.”

Reddy is a seasoned pharmaceutical professional with more than 16 years of experience spanning API sourcing, business development, market expansion and regulatory-driven commercial strategy. He has successfully led high-value markets across India, the Middle East, North Africa, Europe, and the United States, building strong customer partnerships and supporting sustainable revenue growth.

In his new role, Reddy will be responsible for leading ChemWerth’s sales strategy in India and strengthening regional customer relationships. He will also support the company’s focused initiative to roll out new generic APIs in the market, including fermentation, peptide and oncology injectable APIs.

“After reviewing ChemWerth’s strategic plan to unveil a strong pipeline of new generic fermentation, peptide and oncology injectable APIs for the Indian market, I knew that was something I wanted to be a part of,” said Reddy.

About ChemWerth, Inc.:

Established in 1982, ChemWerth is a full-service generic active pharmaceutical ingredient (API) development and supply company providing cGMP-quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India. For more information, please visit www.chemwerth.com.

Chandrakanth Reddy has joined ChemWerth, Inc., as general sales manager of its India office.